Fig. 12
In vivo anti-tumor efficacy of 53D and 53G compared to 53P. Tumor growth curves of A-549 subcutaneous tumors treated in the presence of human PBMCs with (A) 53P (negative control), (B) 53D, and (C) 53G at two different doses (〇: 2 μg/mouse treatment, △: 20 μg/mouse treatment). ●: vehicle (PBS) treatment. Tumor volume was expressed as mean ± standard deviation (SD). *P < 0.05 by Dunnett test (vs vehicle treatment group)